Clinical Trial to Compare the Pharmacokinetics and Pharmacodynamics After Oral Administration of Glucophage and HL-018

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01232036
Recruitment Status : Completed
First Posted : November 2, 2010
Last Update Posted : November 2, 2010
HanAll BioPharma Co., Ltd.
Information provided by:
Asan Medical Center

Brief Summary:
This study is designed to to compare the pharmacokinetic and pharmacodynamic characteristics and safety after oral administration of Glucophage with those after oral administration of HL-018 in healthy male volunteers

Condition or disease Intervention/treatment Phase
Healthy Drug: Glucophage 500mg Drug: HL-018 500mg Other: No administration of Drug Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: A Clinical Trial to Compare the Pharmacokinetic and Pharmacodynamic Characteristics and Safety After Oral Administration of Glucophage With Those After Oral Administration of HL-018 in Healthy Male Volunteers
Study Start Date : May 2010
Actual Primary Completion Date : August 2010
Actual Study Completion Date : October 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: A
Drug: Glucophage 500mg
Single Oral Dose of

Experimental: B
Drug: HL-018 500mg
Single Oral Dose of

Placebo Comparator: C
Other: No administration of Drug

Primary Outcome Measures :
  1. Pharmacokinetics (AUClast and Cmax) [ Time Frame: 24hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   19 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Adult males aged 19 to 50 years at screening.
  • No significant congenital/chronic disease. No symptoms in physical examination.
  • Appropriate subjects as determined by past medical history, laboratory tests, serology and urinalysis.
  • Be able to understand the objective, method of the study, the characteristics of investigational drug, and comply with the requirement of the study. Subject must provide written informed consent prior to study participation.

Exclusion Criteria:

  • History or presence of liver, kidney, or nervous system disease, respiratory disorders, endocrinological disorders, hemato-oncologic, cardiovascular or psychiatric or cognitive disorders.
  • History of gastrointestinal disorders (bleeding, ulceration, hemorrhoids, piles) or disorders of absorption, distribution, metabolism, excretion.
  • History of known hypersensitivity to drugs including metformin.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01232036

Korea, Republic of
Asan Medical Center
Seoul, Korea, Republic of
Sponsors and Collaborators
Asan Medical Center
HanAll BioPharma Co., Ltd.
Principal Investigator: Kyun-Seop Bae, M.D., Ph.D. Asan Medical Center

Additional Information:
Responsible Party: Medical Affairs Department, HanAll Biopharma Co., Ltd. Identifier: NCT01232036     History of Changes
Other Study ID Numbers: 2010-0195
First Posted: November 2, 2010    Key Record Dates
Last Update Posted: November 2, 2010
Last Verified: October 2010

Keywords provided by Asan Medical Center:
healthy volunteers

Additional relevant MeSH terms:
Hypoglycemic Agents
Physiological Effects of Drugs